Pathstone Family Office’s Inovio Pharmaceuticals INO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $57.7K | Buy |
12,366
+8,194
| +196% | +$38.2K | ﹤0.01% | 1620 |
|
|
2023
Q2 | $22.4K | Buy |
4,172
+1,217
| +41% | +$6.52K | ﹤0.01% | 1224 |
|
|
2023
Q1 | $29.1K | Sell |
2,955
-3,688
| -56% | -$36.3K | ﹤0.01% | 1166 |
|
|
2022
Q4 | $124K | Sell |
6,643
-156
| -2% | -$2.92K | ﹤0.01% | 1424 |
|
|
2022
Q3 | $141K | Buy |
6,799
+3,279
| +93% | +$68.2K | ﹤0.01% | 1382 |
|
|
2022
Q2 | $73.1K | Buy |
3,520
+1,840
| +110% | +$38.2K | ﹤0.01% | 1001 |
|
|
2022
Q1 | $72K | Sell |
1,680
-8
| -0.5% | -$343 | ﹤0.01% | 930 |
|
|
2021
Q4 | $101K | Buy |
1,688
+94
| +6% | +$5.62K | ﹤0.01% | 858 |
|
|
2021
Q3 | $137K | Buy |
1,594
+252
| +19% | +$21.7K | ﹤0.01% | 825 |
|
|
2021
Q2 | $149K | Buy |
+1,342
| New | +$149K | ﹤0.01% | 787 |
|